CD34+ cell dose and establishment of full donor chimerism at day +100 are important factors for survival with reduced-intensity conditioning with fludarabine and melphalan before allogeneic hematopoietic SCT for hematologic malignancies

S. G. Holtan, W. J. Hogan, M. A. Elliott, S. M. Ansell, D. J. Inwards, L. F. Porrata, P. B. Johnston, I. N. Micallef, M. Q. Lacy, D. A. Gastineau, M. R. Litzow

Research output: Contribution to journalArticlepeer-review

14 Scopus citations

Fingerprint

Dive into the research topics of 'CD34+ cell dose and establishment of full donor chimerism at day +100 are important factors for survival with reduced-intensity conditioning with fludarabine and melphalan before allogeneic hematopoietic SCT for hematologic malignancies'. Together they form a unique fingerprint.

Keyphrases

Immunology and Microbiology